Bold Insight and The Office of Experience partner to deliver outstanding user experiences.
Back to team page
Sam Alper
Director
Sam’s background in human factors and industrial engineering has led to a systematic approach to problem solving, which considers both the technical and social aspects of challenges, that he applies to each project. He spent the better part of a decade investigating accidents from a human factors perspective, presenting to the Consumer Product Safety Commission and being deposed as an expert witness. Sam has a deep research background and has developed and implemented qualitative and quantitative research methodologies. Sam as a Ph.D. in Industrial and Systems Engineering from the University of Wisconsin—Madison.
Bold facts
Learn more about
Something unique about you summed up in one sentence:
Your favorite part of working at Bold Insight:
In your spare time (or if you had spare time), you would absolutely do this:
How long have you been in the UX field?
Your favorite city in the world is...and why?
Your ultimate celebrity dinner party guest list would include:
Long-term personal or professional goal?
Any other facts to share?
Read our team’s latest bold insights
When designing an experience, are you really thinking about the customer first?
While every organization has constraints to consider when designing experiences for customers or users, designing the ideal customer experience is completely possible within those constraints. Begin by identifying the experience you want your customer to have and work “backward” from there.
UX project logistics: choosing the right vendors for project success
Selecting the correct vendors to support your UX project is critical to success. From facilities to recruiting, knowing the right questions to ask, budget constraints, and client needs and expectations will make the selection process smooth and painless.
Reclassifying diabetes: 3 implications for product design
Recent research suggests that reclassifying diabetes may allow for the development of more targeted diabetes treatments. This could present opportunities to design these treatments to maximize patient safety and experience.